Page last updated: 2024-09-03

3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone and dinoprostone

3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone has been researched along with dinoprostone in 4 studies

Compound Research Comparison

Studies
(3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone)
Trials
(3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone)
Recent Studies (post-2010)
(3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone)
Studies
(dinoprostone)
Trials
(dinoprostone)
Recent Studies (post-2010) (dinoprostone)
250229,1051,3466,357

Protein Interaction Comparison

ProteinTaxonomy3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone (IC50)dinoprostone (IC50)
Prostaglandin E2 receptor EP1 subtypeHomo sapiens (human)0.0155
Prostaglandin E2 receptor EP4 subtypeHomo sapiens (human)0.0031
Prostaglandin E2 receptor EP4 subtypeRattus norvegicus (Norway rat)0.0021
Prostaglandin E2 receptor EP3 subtypeHomo sapiens (human)0.002
Prostaglandin E2 receptor EP2 subtypeHomo sapiens (human)0.0087
Prostacyclin receptorHomo sapiens (human)0.26
Prostaglandin E2 receptor EP2 subtypeRattus norvegicus (Norway rat)0.0052

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's2 (50.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Belley, M; Black, SC; Bosquet, J; Brideau, C; Chan, CC; Cirino, M; Rodger, IW1
Audoly, L; Brideau, C; Chan, CC; Clark, P; Cote, B; Ducharme, Y; Dufresne, L; Gordon, R; Guay, J; Mancini, J; Mullen, AK; Rowland, SE; Xu, D1
Anwyl, R; Ashe, KH; Cleary, J; Cole, G; Falinska, A; Frautschy, S; Kotilinek, LA; Lesne, S; Lim, GP; Panizzon, K; Rowan, M; Simonyi, A; Sun, GY; Wallis, RA; Wang, Q; Westerman, MA; Younkin, LH; Younkin, SG1
Cebrián, C; Escartín, A; Esquivias, P; Esteva, F; García-González, MA; Lanas, A; Morandeira, A; Ortego, J; Piazuelo, E; Santander, S1

Other Studies

4 other study(ies) available for 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone and dinoprostone

ArticleYear
Differential effect of a selective cyclooxygenase-2 inhibitor versus indomethacin on renal blood flow in conscious volume-depleted dogs.
    Journal of cardiovascular pharmacology, 1998, Volume: 32, Issue:5

    Topics: Animals; Blood Pressure; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dogs; Furans; Heart Rate; Indomethacin; Isoenzymes; Male; Prostaglandin-Endoperoxide Synthases; Renal Circulation; Renin

1998
Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic, [3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone], in multiple preclinical species.
    European journal of pharmacology, 2007, Apr-10, Volume: 560, Issue:2-3

    Topics: Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Furans; Gastric Mucosa; Guinea Pigs; Interleukin-1beta; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Rabbits; Rats; Rats, Sprague-Dawley; Stomach

2007
Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity.
    Brain : a journal of neurology, 2008, Volume: 131, Issue:Pt 3

    Topics: Amyloid beta-Peptides; Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Furans; Hippocampus; Ibuprofen; Inflammation Mediators; Interleukin-1beta; Male; Memory; Memory Disorders; Mice; Mice, Inbred C57BL; Naproxen; Neuronal Plasticity; Peptide Fragments; Rats; Synapses; Tumor Necrosis Factor-alpha

2008
Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats.
    World journal of gastroenterology, 2012, Sep-21, Volume: 18, Issue:35

    Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Barrett Esophagus; Cell Transformation, Neoplastic; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Disease Models, Animal; Disease Progression; Esophageal Neoplasms; Esophagitis; Esophagus; Female; Furans; Gastroesophageal Reflux; Indomethacin; Membrane Proteins; Metaplasia; Mucous Membrane; Rats; Rats, Wistar; Time Factors

2012